iSpecimen to Report First Quarter 2024 Financial Results on May 7, 2024
April 25 2024 - 8:00AM
iSpecimen Inc. (Nasdaq: ISPC)
(“iSpecimen” or the “Company”), an online global
marketplace that connects scientists requiring biospecimens for
medical research with a network of healthcare specimen providers,
today announced that it will report its financial results for the
first quarter of 2024 ended March 31, 2024 before the market opens
on Tuesday, May 7, 2024.
The Company will host a conference call and
audio webcast that morning at 8:30 a.m. Eastern Time featuring
remarks by Tracy Curley, CEO.
Event: |
|
iSpecimen
First Quarter 2024 Results Conference Call |
Date: |
|
Tuesday, May 7, 2024 |
Time: |
|
8:30 a.m. Eastern Time |
Dial in: |
|
1-800-717-1738 (U.S. Toll Free) or 1-646-307-1865
(International) |
Webcast: |
|
https://viavid.webcasts.com/starthere.jsp?ei=1666705&tp_key=0ac1c8e17f |
|
|
|
For interested individuals unable to join the
conference call, a replay will be available through May 21, 2024,
at +1-844-512-2921 (U.S. Toll Free) or +1-412-317-6671
(International). Participants must use the following code to access
the replay of the call: 1170104. An archived version of the webcast
will also be available on iSpecimen’s Investor Relations site:
https://investors.ispecimen.com/presentations/.
About iSpecimeniSpecimen
(Nasdaq: ISPC) offers an online marketplace for human biospecimens,
connecting scientists in commercial and non-profit organizations
with healthcare providers that have access to patients and
specimens needed for medical discovery. Proprietary, cloud-based
technology enables scientists to intuitively search for specimens
and patients across a federated partner network of hospitals, labs,
biobanks, blood centers and other healthcare organizations. For
more information, please visit www.ispecimen.com.
Forward Looking Statements
This press release may contain forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Such forward-looking statements are
characterized by future or conditional verbs such as “may,” “will,”
“expect,” “intend,” “anticipate,” believe,” “estimate” and
“continue” or similar words. You should read statements that
contain these words carefully because they discuss future
expectations and plans, which contain projections of future results
of operations or financial condition or state other forward-looking
information.
Forward-looking statements are predictions,
projections and other statements about future events that are based
on current expectations and assumptions and, as a result, are
subject to risks and uncertainties. Many factors could cause actual
future events to differ materially from the forward-looking
statements in this press release, including but not limited to the
risks factors contained in the Company’s filings with the
Securities and Exchange Commission, which are available for review
at www.sec.gov. Forward-looking statements speak only as of
the date they are made. New risks and uncertainties arise over
time, and it is not possible for the Company to predict those
events or how they may affect the Company. If a change to the
events and circumstances reflected in the Company’s forward-looking
statements occurs, the Company’s business, financial condition and
operating results may vary materially from those expressed in the
Company’s forward-looking statements.
Readers are cautioned not to put undue reliance
on forward-looking statements, and the Company assumes no
obligation and does not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events or otherwise.
For further information, please
contact:
Investor ContactKCSA Strategic
CommunicationsPhilip CarlsoniSpecimen@kcsa.com
Media ContactsKCSA Strategic
CommunicationsRaquel Cona / Michaela FawcettiSpecimen@kcsa.com
iSpecimen (NASDAQ:ISPC)
Historical Stock Chart
From Nov 2024 to Dec 2024
iSpecimen (NASDAQ:ISPC)
Historical Stock Chart
From Dec 2023 to Dec 2024